PFA Pension Forsikringsaktieselskab Acquires Shares of 48,330 Insmed, Inc. $INSM

Key Points

• PFA Pension Forsikringsaktieselskab established a new Q4 position in Insmed, buying 48,330 shares worth about $8.41 million.
• Sell‑side analysts are broadly positive on INSM, with a consensus rating of "Buy" and an average price target of $213.23, following several recent target increases.
• Insiders significantly reduced holdings last quarter—selling 174,589 shares valued at roughly $27.44 million (including large sales by the CEO and COO), leaving insiders with about 2.10% ownership.

PFA Pension Forsikringsaktieselskab bought a new position in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 48,330 shares of the biopharmaceutical company's stock, valued at approximately $8,414,000.

Other hedge funds also recently made changes to their positions in the company. CIBC Private Wealth Group LLC raised its position in shares of Insmed by 42.1% in the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 53 shares in the last quarter. CoreCap Advisors LLC bought a new stake in shares of Insmed in the fourth quarter valued at approximately $27,000. Stone House Investment Management LLC acquired a new stake in Insmed during the third quarter worth approximately $29,000. SBI Securities Co. Ltd. grew its position in Insmed by 404.9% during the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 166 shares in the last quarter. Finally, GraniteShares Advisors LLC bought a new position in Insmed during the 4th quarter worth $30,000.

Wall Street Analyst Weigh In

INSM has been the subject of several analyst reports. Jefferies Financial Group started coverage on Insmed in a report on Monday, March 16th. They issued a "buy" rating and a $228.00 price objective for the company. Leerink Partners increased their target price on Insmed from $210.00 to $215.00 and gave the stock an "outperform" rating in a report on Tuesday, March 24th. Stifel Nicolaus raised their price target on Insmed from $205.00 to $208.00 and gave the stock a "buy" rating in a research report on Tuesday, March 24th. Bank of America boosted their price target on Insmed from $211.00 to $213.00 and gave the company a "buy" rating in a research note on Tuesday, March 24th. Finally, Truist Financial set a $205.00 price objective on shares of Insmed in a research note on Monday, January 12th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $213.23.

Insmed Trading Up 5.1%

NASDAQ INSM opened at $140.01 on Tuesday. The company has a market cap of $30.22 billion, a price-to-earnings ratio of -21.84 and a beta of 0.89. Insmed, Inc. has a twelve month low of $63.81 and a twelve month high of $212.75. The company has a quick ratio of 3.54, a current ratio of 3.83 and a debt-to-equity ratio of 0.76. The business's fifty day moving average is $147.89 and its 200 day moving average is $166.24.

Insmed (NASDAQ:INSM - Get Free Report) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($1.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.07) by ($0.47). The firm had revenue of $263.84 million during the quarter, compared to analyst estimates of $263.97 million. Insmed had a negative return on equity of 168.36% and a negative net margin of 210.54%.Insmed's revenue for the quarter was up 152.6% on a year-over-year basis. During the same period in the previous year, the company earned ($1.32) EPS. As a group, sell-side analysts expect that Insmed, Inc. will post -2.51 EPS for the current fiscal year.

Insider Activity

In other news, CEO William Lewis sold 13,396 shares of the company's stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $147.79, for a total value of $1,979,794.84. Following the completion of the transaction, the chief executive officer owned 301,185 shares of the company's stock, valued at $44,512,131.15. This represents a 4.26% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, COO Roger Adsett sold 88,060 shares of the firm's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $164.63, for a total transaction of $14,497,317.80. Following the completion of the transaction, the chief operating officer owned 106,810 shares of the company's stock, valued at approximately $17,584,130.30. This trade represents a 45.19% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 174,589 shares of company stock valued at $27,441,807 over the last quarter. 2.10% of the stock is owned by company insiders.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company's principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.